The Pathophysiology of Chronic Graft-versus-Host Disease

International Journal of Hematology

Volumn 79, Issue 3, 2004, Pages 209-215

  Kansu, Emin ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Autoimmunity; Chronic graft versus host disease; Immune tolerance; Late effects; Stem cell transplantation

Indexed keywords

ALLOANTIGEN; AUTOANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 18;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBODY PRODUCTION; APOPTOSIS; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; GENOMICS; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY; HOMEOSTASIS; HUMAN; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; T LYMPHOCYTE; TH2 CELL; THYMUS ATROPHY; THYMUS FUNCTION;

EID: 2442542523     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.04015     Document Type: Review

References (50)

1. Kansu E, Koç Y, Sullivan KM. Chronic graft-versus-host disease after allogeneic stem cell transplantation. Turk J Cancer. 2003;33: 9-22.
2. Kansu E, Sullivan KM. Late effects of hematopoietic stem cell transplantation. Hematology. 2000;5:1-14.
3. Kansu E, Sullivan KM. Late complications of hematopoietic stem cell transplantation. In: Ho AD, Hass R, Champlin RE, eds, Hematopoietic Stem Cell Transplantation. New York: Marcel Dekker; 2000:413-433.
4. Flowers MED, Kansu E, Sullivan KM. Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am. 1999;13:1091-1112.
5. Lee SJ, Vogelsang G, Flowers MED. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215-233.
6. Socie G, Louisean P, Tamouza R, et al. Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation. 2001;72:699-706.
7. Aractingi S, Chosidow O. Cutaneous graft-versus-host disease. Arch Dermatol. 1998;134:602-612.
8. Ferrara JLM, Cooke KR, Teshima T. The pathophysiology of acute graft-versus-host disease. Int J Hematol. 2003;78:181-187.
9. Parham P, McQueen KL. Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nature Rev Immunol. 2003;3: 108-122.
10. Beschorner WE, Tutschka PJ, Santos GW. Chronic graft-versus-host disease in the rat radiation chimera, I: clinical features, hematology, histology and immunopathology in long-term chimeras. Transplantation. 1982;33:393-399.
11. Tutschka P, Teasdall R, Beschorner WE, Santos GW. Chronic graft-versus-host disease in the rat radiation chimera. Transplantation. 1982;34:289-294.
12. Beschorner W, Tutschka, PJ, Santos GW. Chronic graft-versus-host disease in the rat radiation chimera, III: immunology and immunopathology in rapidly induced models. Transplantation. 1983;35:224-230.
13. Gleichmann E, Gleichmann H, Wilke W. Autoimmunization and lymphomagenesis in parent-to-F1 combinations differing at the major histocompatibility complex: model for spontaneous disease caused by altered self-antigens? Transplant Rev. 1976;31:156-224.
14. Via CS, Shearer GM. T-cell interactions in autoimmunity: insights from a murine model of graft-versus-host disease. Immunol Today. 1988;9:207-213.
15. Gleichmann E, Pals ST, Rolink AG, Radaszkiewicz T, Gleichmann H. Graft-versus-host reactions: clues to the etiopathology of a spectrum of immunologic diseases. Immunol Today. 1984;5:324-332
16. De Wit D, Van Mechelen M, Zanin C, et al. Preferential activation of Th2 cells in chronic graft-versus-host reaction. J Immunol. 1993; 150:361-366.
17. + T cell. J Immunol. 1995;155:2396-2406.
18. + T-cell activation and IFN-gamma production. J Immunol. 1998;161: 2848-2855.
19. Slayback DL, Dobkins JA, Harper JM. Genetic factors influencing the development of chronic graft-versus-host disease in a murine model. Bone Marrow Transplant. 2000;26:931-938.
20. Kamradt T, Mitchison NA. Tolerance and autoimmunity. N Engl J Med. 2001;344:655-664.
21. Parkman R, Weinberg KI. Immune reconstitution following hematopoietic cell transplantation. In: Blume KG, Forman SJ, Appelbaum FR, eds. Thomas' Hematopoietic Cell Transplantation. 3rd ed. Oxford: Blackwell Publishing; 2004:853-861.
22. Weinberg K, Blazar BR, Wagner JE, et al. Factors affecting thymic function after allogeneic stem cell transplantation. Blood. 2001;97: 1458-1466.
23. Sullivan KM. Graft-versus-host disease. In: Blume KG, Forman SJ, Appelbaum FR, eds. Thomas' Hematopoietic Cell Transplantation. 3rd ed. Oxford: Blackwell Publishing; 2004:635-664.
24. Atkinson K, Incefy GS, Storb R, et al. Low serum thymic hormone levels in patients with chronic graft-versus-host disease. Blood. 1982;59:1073-1077.
25. Hess A, Thoburn C, Chen W, Horwitz L. Autoreactive T-cell subsets in acute and chronic syngeneic graft-versus-host disease. Transpl Proc. 2001;33:1754-1756.
26. Graze PR, Gale RP. Chronic graft-versus-host disease: a syndrome of disordered immunity Am J Med. 1979;66:611-620.
27. Lister J, Messner H, Keysteon E, Miller R, Fritzler MJ. Autoantibody analysis of patients with graft-versus-host disease. J Clin Lab Immunol. 1987;24:19-23.
28. Kier P, Penner E, Bakos S, et al. Autoantibodies in chronic GVHD: high prevalance of antinucleolar antibodies. Bone Marrow Transplant. 1990;6:93-96.
29. Bell SA, Faust H, Mittermuller J, Kolb H-J, Meurer M. Specificity of antinuclear antibodies in scleroderma-like chronic graft-versus-host disease: clinical correlation and histocompatibility locus antigen association. Br J Dermatol. 1996;134:848-854.
30. Wesierska-Gadek J, Penner E, Hitchman E, Kier P, Sauermann G. Nucleolar proteins B23 and C23 as target antigens in chronic graft-versus-host disease. Blood. 1992;79:1081-1086.
31. Rouquette-Gally AM, Boyeldieu D, Prost AC, Gluckman E. Autoimmunity after allogeneic bone marrow transplantation: a study of 53 long-term-surviving patients. Transplantation. 1988;46: 238-240.
32. Santamaria P. Cytokines and chemokines in autoimmune disease: an overview. In: Santamaria P, ed. Cytokines and Chemokines in Autoimmune Diseases. New York: Academic/Plenum Publishers; 2003:1-7.
33. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol. 1998;16:137-161.
34. Zhang Y, McCormick LM, Desai SR, Wu C, Gilliam AC. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines and immune cell activation. J Immunol. 2002;168:3088-3098.
35. Athie-Morales V, Smits HH, Cantrell DA, Hilkens CMU. Sustained IL-12 signaling is required for Th1 development. J Immunol. 2004; 172:61-69.
36. Williamson E, Garside P, Bradley JA, Mowat AM. IL-12 is a central mediator of acute graft-versus-host disease in mice. J Immunol. 1996;157:689-699.
37. Via CS, Rus V, Gately MK, Finkelman FD. IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease. J Immunol. 1994;153:4040-4047.
38. Lauwerys BR, Renauld J-C, Houssiau FA. Inhibition of in-vitro immunoglobulin production by IL-12 in murine chronic graft-versus-host disease: synergism with IL-18. Eur J Immunol. 1998; 28:2017-2024.
39. Okamura H, Tsutsui H, Komastu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T-cells. Nature. 1995;378: 88-91.
40. Dinarello CA. Interleukin-18. Methods. 1999;19:121-132.
41. Akira S. The role of IL-18 in innate immunity. Curr Opin Immunol. 2000;12:59-63.
42. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol. 2001; 19:423-474.
43. Reddy P, Tshima T, Hildebrandt G, et al. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood. 2003; 101:2877-2885.
44. Okamoto I, Kohno K, Tanimoto T, et al. IL-18 prevents the development of chronic graft-versus-host disease in mice. J Immunol. 2000;164:6067-6074.
45. Reid SD, Penna G, Adorini L. The control of T-cell responses by dendritic cell subsets. Curr Opin Immunol. 2000;12:114-121.
46. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002;20:621-667.
47. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811.
48. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A. 2002;99:351-358.
49. Ferrara JL, Cooke KR, Pan L, Krenger W. The immunopathophysiology of acute graft-versus-host disease. Stem Cells. 1996;14: 473-489.
50. Chan GW, Gorgun G, Miller KB, Foss FM. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:170-176.